clinical trial · NCT07387081
Phase II Study of LM-24C5
Advanced Solid Tumor CancerLM-24C5LM-24C5
brief summary
This study is to evaluate the efficacy and safety of the LM-24C5 in combination with other therapies in subjects with CEACAM5-positive advanced solid tumor
started
Dec 15, 2025
primary completion
May 21, 2028
completion
Oct 25, 2028
last updated
Feb 4, 2026
official title
An Open-label, Multicenter Phase II Clinical Study to Evaluate the Efficacy, Safety, and Tolerability of LM-24C5 in Combination With Other Anti-tumor Treatment in Subjects With CEACAM5-positive Advanced Solid Tumors
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol